Trial Profile
A Phase IB/II Multicenter, Two-Arm, Dose-Escalation Study of Oral AEE788 Administered in Combination With Oral RAD001 on a Continuous Once Daily Dosing Schedule in Adult Patients With First or Second Recurrent or Relapsing Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs AEE 788 (Primary) ; Everolimus (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 30 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2007 Status change
- 18 Aug 2005 New trial record.